Olmesartan Medoxomilo + Hidroclorotiazida Tolife (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil and hydrochlorothiazide, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Tolife, is an Angiotensin II receptor blocker and thiazide diuretic presented as a combined oral tablet for systemic use. It treats hypertension in adult patients.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Tolife as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxil combined with Hydrochlorothiazide is used to manage high blood pressure by targeting the renin‑angiotensin system and promoting diuresis.

- Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension. - Resistant hypertension: provides additional blood‑pressure control when monotherapy is insufficient. - Hypertension with fluid retention: reduces plasma volume and vascular resistance, improving overall control.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first doses. - Headache: mild to moderate intensity, often resolves with continued therapy. - Increased urination: due to the diuretic component, may be noticeable initially. - Electrolyte imbalance: mild reductions in potassium or sodium levels.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or airway requiring immediate medical attention. - Severe dehydration: excessive fluid loss leading to hypotension. - Acute kidney injury: sudden decline in renal function, especially in patients with pre‑existing kidney disease. - Hyperkalemia: elevated potassium levels, potentially dangerous if untreated. - Severe hypotension: marked drop in blood pressure causing fainting or shock.

Before initiating therapy, consider the following precautions: - Monitor blood pressure: ensure adequate control and avoid excessive lowering. - Assess renal function: check serum creatinine and eGFR periodically. - Check electrolytes: especially potassium and sodium levels during treatment. - Use caution in hepatic impairment: dose adjustments may be needed. - Avoid in severe dehydration: rehydrate before starting the combination. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil + Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren: combined use can cause excessive potassium elevation and renal impairment. - Potassium‑sparing diuretics (e.g., spironolactone): risk of hyperkalemia. - Lithium: increased lithium levels may lead to toxicity. - ACE inhibitors: additive effect on potassium and renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may cause additive blood‑pressure lowering. - Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment. - CYP450 inhibitors (e.g., ketoconazole): may increase olmesartan plasma concentrations.